Introduction
The definition of "epileptic myoclonus" has changed several times over the past 3 decades. Myoclonus is currently defined as sudden involuntary jerking of a muscle or groups [2] . Myoclonus is associated with multiple epilepsy syndromes such as juvenile myoclonic epilepsy and the progressive myoclonic epilepsies. Although the neurophysiology of myoclonus is incompletely understood [1] , spatial and temporal amplification within relevant networks may cause the epileptic motor activity. [3] .
Recently, graft versus host disease was observed to cause central nervous system (CNS) complications following allogenic stem cell transplants (allo-HSCTs) [4] [5] [6] [7] [8] [9] . However, very few patients have presented with myoclonus [6, 9] . We describe an allo-HSCT patient who developed chronic GVHD, associated with intractable myoclonic seizures. This appears to be an uncommon example of symptomatic myoclonic epilepsy, defined as clinical myoclonus associated with diffuse polyspike activity on EEG following a known cerebral insult.
Case
A 48-year-old male was diagnosed with Philadelphia chromosome positive acute myelogenous leukemia in 9/03/2008. He received a 7 + 3 induction chemotherapy (3 days of daunorubicin and 7 days of continuous infusion of cytosine arabinoside) in September with 400 mg of imatinib given for 14 days of the induction. A bone marrow on 10/23/2008 was consistent with a complete remission -there was no morphological evidence of residual acute leukemia. At that time, quantitative PCR for bcr-abl p210, previously positive, was negative. Imatinib was resumed at 800 mg daily. The patient subsequently remained in complete morphological and molecular remission of his leukemia. He then received nonmyeloablative conditioning chemotherapy with fludarabine and cyclophosphamide prior to allogenic stem cell transplantation with matched unrelated donor stem cells on 2/23/09 without incident. He remained stable and tolerated the course well.
The patient recovered normal hematopoiesis rapidly, but donor engraftment as documented by XY fluorescence in-situ hybridization (FISH) was initially modest -XX was initially only 1.4%.
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In June 2012, the patient presented with myoclonic jerks involving his arms and legs. They caused occasional falls, but he denied any loss of consciousness. In spite of levetiracetam, he continued to have episodes multiple times per day. He was admitted to the neurology service after a myoclonic jerk that resulted in a fall with loss of consciousness. His neurological exam was unremarkable except for frequent myoclonic jerks of the extremities with brief alteration in awareness and responsiveness. Brain magnetic resonance imaging revealed periventricular white matter lesions (Fig. 1) . Electroencephalography showed frequent generalized 40-70 uV polyspike activity that occurred in runs lasting from 0.5-3 s, maximal in the frontocentral regions (Fig. 2) . This activity was seen spontaneously and during photic stimulation. Perampanel improved his symptoms by 40%. However, his seizures then worsened and were intractable to levetiracetam, valproic acid, topiramate, lorazepam, clonazepam, zonisamide, and lacosamide. Vagal nerve stimulation did not improve the frequency or severity of the myoclonic jerks. For chronic oral graft versus host disease, the patient requires ongoing immunosuppression with tacrolimus, mycophenolate, and oral topical dexamethasone. Attempts to taper tacrolimus have resulted in problematic ulcerative oral inflammation. In spite of immunosuppressive agents, he experiences some ongoing oral mucosal irritation.
Discussion
Chronic GVHD is recognized to cause neurological manifestations [4] [5] [6] [7] [8] [9] , but little is known about its relationship with symptomatic myoclonus, resulting in a scarcity of information of the natural history or treatment outcomes. Initially, our patient received partial relief from perampanel, but his condition proved to be intractable to more than eight antiepileptic drugs and vagal nerve stimulation. He continues to have 3 or more seizures per hour, resulting in up to 100 per day. We summarize several case studies written within the last 30 years in Table 1 . However, nearly all reported patients have died or are still suffering from severe epilepsy. Further research is needed to determine an appropriate protocol for patients who develop myoclonus following GVHD.
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